Written by
Strainprint was recently featured on Business of Cannabis where both our President, David Berg, and CEO, Andrew Muroff were interviewed as part of their BofC Asked Series.
Have a look at what they had to say about the current Business of Cannabis.
BofC // Asked Drew
BofC // Asked Dave
Coinciding with the adult use legalization of cannabis across North America, an opioid epidemic has emerged. It is estimated that more than 130 people die each day due to opioid overdose in the United States alone, according to the U.S. Department of Health and Human Services (HHS). The organization reported that, in 2017, nearly 50,000 Americans died […]
Camphene, sometimes called comphene, is one of more than 200 terpenes discovered to date in hemp and cannabis. Terpenes are aromatic molecules once thought to convey only aroma and, from an evolutionary functional perspective, to protect a plant from pests and predators. In recent years, however, much clinical research, in addition to anecdotal evidence, has […]
Welcome to the Strainprint Community Understanding Terpenes Series. Before diving into the details behind beta-caryophyllene (BCP, caryophyllene, or β-caryophyllene), the molecule produced by cannabis known for its categorization as both a terpene and a cannabinoid that provides pain killing and anti-inflammatory benefits, it behooves readers to develop a solid understanding of terpenes as a category of wellness molecule. Patients […]